細胞バンク(東北大学・加藤研究室)

AMED創薬等支援技術基盤プラットフォームは、これまで実施されてきた構造生物学分野のプロジェクト成果を継承・発展させ、創薬プロセス等に活用可能な技術基盤の整備、積極的な外部開放等を行うことで、創薬・医療技術シーズ等を着実かつ迅速に医薬品等に結び付ける革新的プロセスを実現することを目的としております。

本事業は平成28年度で終了となりますが、東北大学・加藤研究室は、全国のライフサイエンス研究者の支援を事業終了後も可能な限り継続していきます。

本セルバンクは、AMED創薬等支援技術基盤プラットフォーム生産領域・東北大学・加藤研究室(代表研究者:大阪大学・高木淳一)の成果の一部です。以下の細胞は、簡単なMTA(AMED謝辞記載、再分譲不可、販売不可、など)を交わすことで供与可能です。

担当者連絡先:東北大学地域イノベーション 加藤 幸成
E-mail:yukinarikato@gmail.com

抗体バンクもご覧下さい。

Cell nameParental cellsTargeted genesGenom editingDeficient
PDIS-1 HEK-293T hsMgat1/GnT-1 TALEN N-glycan
PDIS-2 HEK-293T PDPN CRISPR/Cas9 PDPN
PDIS-4 COS-7 PDPN CRISPR/Cas9 PDPN
PDIS-6 LN319 PDPN CRISPR/Cas9 PDPN
PDIS-9 CHO-S hsMgat1/GnT-1 TALEN N-glycan
PDIS-12 HEK-293T hsMgat1/GnT-1 TALEN N-glycan
PDIS-14 CHO-S SLC35A1 CRISPR/Cas9 sialic acid
PDIS-22 HEK-293T SLC35A1 CRISPR/Cas9 sialic acid

*すでに30種類以上樹立しておりますが、論文を発表したものに限り分譲をしております。次々に発表していきますので、随時ご確認ください。

参考文献

  • PDIS-1
    1. Kaneko MK, Nakamura T, Honma R, Ogasawara S, Fujii Y, Abe S, Takagi M, Harada H, Suzuki H, Nishioka Y, Kato Y. Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin using glycan-deficient cell lines generated by CRISPR/Cas and TALEN. Cancer Med., in press
  • PDIS-2
    1. Kaneko MK, Nakamura T, Honma R, Ogasawara S, Fujii Y, Abe S, Takagi M, Harada H, Suzuki H, Nishioka Y, Kato Y. Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin using glycan-deficient cell lines generated by CRISPR/Cas and TALEN. Cancer Med., in press
    2. Fujii Y, Matsunaga Y, Arimori T, Kitago Y, Ogasawara S, Kaneko MK, Kato Y, Takagi J. Tailored placement of a turn-forming PA tag into the structured domain of a protein to probe its conformational state. J Cell Sci, 29, 1512-1522, 2016
    3. Ogasawara S, Kaneko MK, Kato Y. LpMab-19 Recognizes Sialylated O-glycan on Thr76 of Human Podoplanin. Monoclon. Antib. Immunodiagn. Immunother., DOI: 10.1089/ mab.2016.0031., 2016
    4. Ogasawara S, Kaneko MK, Honma R, Oki H, Fujii Y, Takagi M, Suzuki H, Kato Y.* Establishment of Mouse Monoclonal Antibody LpMab-13 against Human Podoplanin. Monoclon. Antib. Immunodiagn. Immunother., 35(3):155-162, 2016
    5. Kato Y*, Ogasawara Y, Oki H, Honma R, Takagi M, Fujii Y, Nakamura T, Saidoh N, Kanno H, Umetsu M, Kamata S, Kubo H, Yamada M, Sawa Y, Morita K, Harada H, Suzuki H, Kaneko MK. Novel Monoclonal Antibody LpMab-17 Developed by CasMab Technology Distinguishes Human Podoplanin from Monkey Podoplanin. Monoclon. Antib. Immunodiagn. Immunother., 35(2), 109-116, 2016
    6. Kato Y, Ogasawara S, Oki H, Goichberg P, Honma R, Fujii Y, Kaneko MK. LpMab-12 Established by CasMab Technology Specifically Detects Sialylated O-glycan on Thr52 of Platelet Aggregation-stimulating Domain of Human Podoplanin. PLoS One, 11(3), e0152912, 2016
  • PDIS-4
    1. Kato Y, Ogasawara S, Oki H, Goichberg P, Honma R, Fujii Y, Kaneko MK. LpMab-12 Established by CasMab Technology Specifically Detects Sialylated O-glycan on Thr52 of Platelet Aggregation-stimulating Domain of Human Podoplanin. PLoS One, 11(3), e0152912, 2016
  • PDIS-6
    1. Kaneko MK, Yamada S, Nakamura T, Abe S, Nishioka Y, Kunita A, Fukayama M, Fujii Y, Ogasawara S, Kato Y*. Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity. Cancer Med., in press
    2. Kaneko MK, Nakamura T, Honma R, Ogasawara S, Fujii Y, Abe S, Takagi M, Harada H, Suzuki H, Nishioka Y, Kato Y. Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin using glycan-deficient cell lines generated by CRISPR/Cas and TALEN. Cancer Med., in press
    3. Ogasawara S, Kaneko MK, Kato Y. LpMab-19 Recognizes Sialylated O-glycan on Thr76 of Human Podoplanin. Monoclon. Antib. Immunodiagn. Immunother., DOI: 10.1089/ mab.2016.0031., 2016
    4. Ogasawara S, Oki H, Kaneko MK, Hozumi Y, Liu X, Honma R, Fujii Y, Nakamura T, Goto K, Takagi M, Kato Y*. Development of a monoclonal antibody LpMab-10 recognizing non-glycosylated PLAG1/2 domain including Thr34 of human podoplanin. Monoclon. Antib. Immunodiagn. Immunother., 34(5), 318-326, 2015
    5. Kaneko MK, Oki H, Hozumi Y, Liu X, Ogasawara S, Takagi M, Goto K, Kato Y* A monoclonal antibody LpMab-9 recognizes O-glycosylated N-terminus of human podoplanin. Monoclon. Antib. Immunodiagn. Immunother., 34(5), 310-317, 2015
    6. Kato Y, Ogasawara S, Oki H, Goichberg P, Honma R, Fujii Y, Kaneko MK. LpMab-12 Established by CasMab Technology Specifically Detects Sialylated O-glycan on Thr52 of Platelet Aggregation-stimulating Domain of Human Podoplanin. PLoS One, 11(3), e0152912, 2016
  • PDIS-9
    1. Kaneko MK, Yamada S, Nakamura T, Abe S, Nishioka Y, Kunita A, Fukayama M, Fujii Y, Ogasawara S, Kato Y*. Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity. Cancer Med., in press
    2. Kaneko MK, Nakamura T, Honma R, Ogasawara S, Fujii Y, Abe S, Takagi M, Harada H, Suzuki H, Nishioka Y, Kato Y. Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin using glycan-deficient cell lines generated by CRISPR/Cas and TALEN. Cancer Med., in press
  • PDIS-12
    1. Kaneko MK, Nakamura T, Honma R, Ogasawara S, Fujii Y, Abe S, Takagi M, Harada H, Suzuki H, Nishioka Y, Kato Y. Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin using glycan-deficient cell lines generated by CRISPR/Cas and TALEN. Cancer Med., in press
  • PDIS-14
    1. Kaneko MK, Yamada S, Nakamura T, Abe S, Nishioka Y, Kunita A, Fukayama M, Fujii Y, Ogasawara S, Kato Y*. Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity. Cancer Med., in press
    2. Kaneko MK, Nakamura T, Honma R, Ogasawara S, Fujii Y, Abe S, Takagi M, Harada H, Suzuki H, Nishioka Y, Kato Y. Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin using glycan-deficient cell lines generated by CRISPR/Cas and TALEN. Cancer Med., in press
  • PDIS-22
    1. Kaneko MK, Nakamura T, Honma R, Ogasawara S, Fujii Y, Abe S, Takagi M, Harada H, Suzuki H, Nishioka Y, Kato Y. Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin using glycan-deficient cell lines generated by CRISPR/Cas and TALEN. Cancer Med., in press